MONO: Symbicort® Single inhaler Therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults

Study identifier:D5890L00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A comparison of the efficacy of Symbicort® Single inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 inhalation b.i.d. plus as-needed) and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. A randomized, open, parallel-group, multicentre 26-weeks study

Medical condition

asthma

Phase

Phase 4

Healthy volunteers

No

Study drug

Budesonide/Formoterol Turbuhaler, Conventional Best Asthma Therapy

Sex

All

Actual Enrollment

1900

Study type

Interventional

Age

12 Years +

Date

Study Start Date: 01 Sept 2004
Primary Completion Date: 01 Oct 2006
Study Completion Date: 01 Oct 2006

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria